Yan Dai, PhD
Assistant Professor
Boston University School of Medicine
Dept of Medicine
Hematology & Medical Oncology

PhD, Beijing Medical University
MS, Hebei University



My research interest is to understand the mechanism of cancer cell growth and metastasis and explore how epigenetic regulation control gene expression including fetal globin gene silencing in sickle cell disease. We have two areas of research interest:
1) Understand the mechanism of cancer cell growth, invasion and metastasis to identify new target in cancer treatment, particularly focus on prostate cancer and breast cancer. We employ two experimental systems including 2-D or 3-D cultured primary and cancer cell lines, as well as mice models integrated with a number of epigenetic, molecular, and cell biology approaches to pursue in our studies. Expertise includes: Orthotopic mouse models of human prostate cancer and human breast cancer; Experimental metastasis mouse model; Human xenograft tumor mouse model; 3D culture of tumor cell growth and invasion; epigenetic regulation (acetylation, methylation and chromatin immunoprecipitation assays), Chromosome conformation capture (3C) assay.

2) Understand the mechanism of controlling fetal hemoglobin gene expression to identify new targets in the sickle cell disease and thalassemia treatment. We used erythroid progenitor cells or induced pluripotent stem (iPS) cells from sickle cell or thalassemia patients and cord blood, to determine the efficacy of small molecules compounds in fetal hemoglobin induction, and determine the mechanism that control locus control region (LCR) looping and transcription complex formation in LCR and fetal hemoglobin promoter.


Boston University Clinical and Translational Science Award (CTSA) Program UL1
05/01/2008 - 04/30/2012 (PI of Sub-Project / SP)
PI: David M. Center, MD
NIH/National Center for Health Research
3UL1RR025771-04

Role of HIC1 in Suppression of Breast Cancer Growth and Tamoxifen Resistance
09/01/2009 - 08/31/2011 (PI)
NIH/National Cancer Institute
5 R21 CA129046 02



Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Dai Y, Chen T, Ijaz H, Cho EH, Steinberg MH. SIRT1 activates the expression of fetal hemoglobin genes. Am J Hematol. 2017 Nov; 92(11):1177-1186.View Related Profiles. PMID: 28776729.
  2. Dai Y, Sangerman J, Nouraie M, Faller AD, Oneal P, Rock A, Owoyemi O, Niu X, Nekhai S, Maharaj D, Cui S, Taylor R, Steinberg M, Perrine S. Effects of hydroxyurea on F-cells in sickle cell disease and potential impact of a second fetal globin inducer. Am J Hematol. 2017 Jan; 92(1):E10-E11.View Related Profiles. PMID: 27766663; DOI: 10.1002/ajh.24590;.
  3. Cho EH, Dai Y. SIRT1 controls cell proliferation by regulating contact inhibition. Biochem Biophys Res Commun. 2016 Sep 16; 478(2):868-72. PMID: 27514448; DOI: 10.1016/j.bbrc.2016.08.041;.
  4. Boosalis MS, Sangerman JI, White GL, Wolf RF, Shen L, Dai Y, White E, Makala LH, Li B, Pace BS, Nouraie M, Faller DV, Perrine SP. Novel Inducers of Fetal Globin Identified through High Throughput Screening (HTS) Are Active In Vivo in Anemic Baboons and Transgenic Mice. PLoS One. 2015; 10(12):e0144660.View Related Profiles. PMID: 26713848; PMCID: PMC4694699; DOI: 10.1371/journal.pone.0144660;.
  5. Dai Y, Sangerman J, Luo HY, Fucharoen S, Chui DH, Faller DV, Perrine SP. Therapeutic fetal-globin inducers reduce transcriptional repression in hemoglobinopathy erythroid progenitors through distinct mechanisms. Blood Cells Mol Dis. 2016 Jan; 56(1):62-9.View Related Profiles. PMID: 26603726; PMCID: PMC4667977; DOI: 10.1016/j.bcmd.2015.10.004;.
  6. Zhu L, Qi J, Chiao CY, Zhang Q, Porco JA, Faller DV, Dai Y. Identification of a novel polyprenylated acylphloroglucinol-derived SIRT1 inhibitor with cancer-specific anti-proliferative and invasion-suppressing activities. Int J Oncol. 2014 Nov; 45(5):2128-36.View Related Profiles. PMID: 25189993; PMCID: PMC4203335; DOI: 10.3892/ijo.2014.2639;.
  7. Zhu L, Chiao CY, Enzer KG, Stankiewicz AJ, Faller DV, Dai Y. SIRT1 inactivation evokes antitumor activities in NSCLC through the tumor suppressor p27. Mol Cancer Res. 2015 Jan; 13(1):41-9.View Related Profiles. PMID: 25143434; PMCID: PMC4312526; DOI: 10.1158/1541-7786.MCR-14-0239;.
  8. Lovaas JD, Zhu L, Chiao CY, Byles V, Faller DV, Dai Y. SIRT1 enhances matrix metalloproteinase-2 expression and tumor cell invasion in prostate cancer cells. Prostate. 2013 Apr; 73(5):522-30.View Related Profiles. PMID: 23038275; DOI: 10.1002/pros.22592;.
  9. Byles V, Zhu L, Lovaas JD, Chmilewski LK, Wang J, Faller DV, Dai Y. SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis. Oncogene. 2012 Oct 25; 31(43):4619-29.View Related Profiles. PMID: 22249256; DOI: 10.1038/onc.2011.612;.
  10. Moore RL, Dai Y, Faller DV. Sirtuin 1 (SIRT1) and steroid hormone receptor activity in cancer. J Endocrinol. 2012 Apr; 213(1):37-48.View Related Profiles. PMID: 22159506; PMCID: PMC3804056; DOI: 10.1530/JOE-11-0217;.
Showing 10 of 19 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 19 publications over 13 distinct years, with a maximum of 2 publications in 2001 and 2008 and 2012 and 2014 and 2015 and 2016

YearPublications
19991
20012
20031
20051
20071
20082
20101
20111
20122
20142
20152
20162
20171
Contact for Mentoring:


72 E. Concord St Instructional (L)
Boston MA 02118
Google Map


Dai's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department